Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 34.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 92,104 shares of the company's stock after purchasing an additional 23,834 shares during the period. Fisher Asset Management LLC owned approximately 0.09% of Neurocrine Biosciences worth $12,572,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. State Street Corp boosted its stake in shares of Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company's stock worth $593,186,000 after acquiring an additional 539,936 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Neurocrine Biosciences by 145.1% during the 4th quarter. Jennison Associates LLC now owns 820,694 shares of the company's stock worth $112,025,000 after acquiring an additional 485,894 shares during the period. Los Angeles Capital Management LLC boosted its holdings in Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company's stock valued at $48,479,000 after purchasing an additional 363,863 shares during the last quarter. Impax Asset Management Group plc grew its position in Neurocrine Biosciences by 207.8% in the fourth quarter. Impax Asset Management Group plc now owns 261,599 shares of the company's stock worth $35,708,000 after acquiring an additional 176,599 shares during the period. Finally, Braidwell LP increased its position in shares of Neurocrine Biosciences by 20.9% during the 3rd quarter. Braidwell LP now owns 917,674 shares of the company's stock worth $105,734,000 after purchasing an additional 158,665 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now owns 2,507 shares in the company, valued at approximately $338,445. The trade was a 30.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Julie Cooke sold 1,740 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.89, for a total transaction of $266,028.60. Following the sale, the insider now directly owns 18,202 shares of the company's stock, valued at approximately $2,782,903.78. This trade represents a 8.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 234,269 shares of company stock valued at $34,053,879 over the last ninety days. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $185.00 target price on shares of Neurocrine Biosciences in a research note on Friday, February 21st. William Blair restated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Morgan Stanley restated an "overweight" rating and issued a $150.00 price objective (down previously from $185.00) on shares of Neurocrine Biosciences in a research note on Friday. StockNews.com downgraded shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 18th. Finally, Wedbush cut their price objective on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $165.24.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX traded up $0.38 on Friday, reaching $113.04. The stock had a trading volume of 1,650,716 shares, compared to its average volume of 1,346,984. The company has a market cap of $11.27 billion, a price-to-earnings ratio of 34.36, a P/E/G ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 12-month low of $110.25 and a 12-month high of $157.98. The firm's fifty day moving average is $133.00 and its two-hundred day moving average is $127.59.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. As a group, research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences announced that its board has authorized a share buyback plan on Friday, February 21st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.